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Abstract 
Alzheimer’s disease accounts for 60–70% of cases of dementia worldwide, with an estimated 
global incidence of 50 million cases. Alzheimer’s disease is a chronic and fatal illness that 
causes progressive deterioration of the central nervous system. Cholinergic deficiency is 
associated with Alzheimer’s disease, and various cholinesterase inhibitors have been developed 
as lead compounds for the treatment of Alzheimer’s disease, including naturally derived 
inhibitors, synthetic analogues and hybrids. Due to the multifactorial nature of Alzheimer’s 
disease, no cure is available for this fatal disease despite huge efforts by the pharmaceutical 
industry and academia. Indeed, nowadays, the health care system is only able to alleviate the 
symptoms of Alzheimer’s disease patients by providing drugs which belong to the class of 
drugs called acetylcholinesterase inhibitors. 
 
Through recent studies it has been shown that iminosugars armed with suitable hydrophobic 
groups behave as very potent acetylcholinesterase inhibitors. Inspired by the very potent 
acetylcholinesterase inhibitor edrophonium 1 that hosts a permanent positive charge in its 
ammonium group, in this thesis we aimed to convert an iminosugar into an ammonium 
compound 11 that also hosts a permanent positive charge on its nitrogen atom. Compound 11 
was successfully synthesized in seven steps starting from commercially available L-xylose in 
an overall total yield of 8%. The synthetic strategy for achieving this was to treat the pyrrolidine 
9 with 1,4-dibromobutane and Pd/C catalyzed reduction, which triggered the N-spiro 
cyclization of the iminosugar into a quaternary ammonium salt 11 hosting a positive charge on 
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AChEI – Acetylcholinesterase inhibitor 
BuChE – Butyrylcholinesterase 
CAS – Catalytic anionic subsite 
ChAT – Choline acetyltransferase 
DCM – Dichloromethane 
DMF – N,N-Dimethylformamide 
Et – Ethyl  
IR – Infrared  
Me – Methyl  
NMR – Nuclear magnetic resonance 
PAS – Peripheral anionic site  
PE – Petroleum ether 
RT – Room temperature 
TBAF – Tetra-n-butylammonium fluoride 
TcAChE – Torpedo californica acetylcholinesterase 
THF - Tetrahydrofuran 
TLC – Thin-layer chromatography 








     
Contents 
1  Introduction ................................................................................................................................................... 7 
1.1 Alzheimer’s disease ........................................................................................................................................ 7 
1.2 AD’s Neuropathology .................................................................................................................................... 8 
1.3 Cholinergic and Amyloid Hypothesis ............................................................................................................ 9 
1.3.1 Cholinesterase and Cholinergic Hypothesis ........................................................................................... 9 
1.3.2 Amyloid Hypothesis ............................................................................................................................. 11 
1.4 The mechanism of AChE .............................................................................................................................. 12 
1.5 Traditional AChE Inhibitors ........................................................................................................................ 14 
1.5.1 Physostigmine ...................................................................................................................................... 15 
1.5.2 Tacrine .................................................................................................................................................. 15 
1.5.2b Synthesis of Tacrine ........................................................................................................................... 16 
1.5.3 Donepezil ............................................................................................................................................. 16 
1.5.4 Rivastigmine ........................................................................................................................................ 17 
1.5.5 Galantamine ......................................................................................................................................... 17 
1.5.6 Metrifonate ........................................................................................................................................... 17 
1.6 The future of AChE inhibitor ....................................................................................................................... 18 
1.8 Iminosugars .................................................................................................................................................. 19 
Objectives ........................................................................................................................................................... 20 
2  Results and discussion ................................................................................................................................ 21 
2.1.1 Protection of L-xylose to give the tetra-protected sugar 3 ................................................................... 21 
2.1.2 Condensation-silyl protection reaction sequence ................................................................................. 22 
2.1.3 Mesylation protection of compound 5 to yield compound 6 ............................................................... 24 
2.1.4 Cyclisation to form zwitterion 7 .......................................................................................................... 25 
2.1.5 Reduction and deoxygenation reaction ................................................................................................ 26 
2.1.6 Formation of the target N-spiro fused compound 10 via double substitution reaction ........................ 27 
2.1.7 Benzyl deprotection to furnish target molecule 11 .............................................................................. 29 
2.2 Concluding remarks ..................................................................................................................................... 30 
2.3 Future work .................................................................................................................................................. 30 
3  Experimental ............................................................................................................................................... 31 
3.1  General ............................................................................................................................................ 31 
3.1.1 Solvents and reagents ........................................................................................................................... 31 
3.1.2 Spectroscopic and spectrometric analysis ............................................................................................ 31 
3.1.3 Chromatography ................................................................................................................................... 31 
3.2 Methods ........................................................................................................................................................ 32 
3.2.1 2,3,5-Tri-O-benzyl-L-xylofuranose (3) ................................................................................................ 32 
3.2.2 (2R,3R,4S,E)-2,3,5-Tris(benzyloxy)-4-hydroxypentanal O-(tert-butyldiphenylsilyl) oxime (5) ........ 33 
3.2.3 (2R,3R,4S,E)-2,3,5-Tris(benzyloxy)-4-metylsulfonyloxypentanal O-(tert-butyldiphenylsilyl) oxime 
(6) .................................................................................................................................................................. 34 
3.2.4 (2R,3R,4R)-3,4-Bis(benzyloxy)-2-((benzyloxy)methyl)-3,4-dihydro-2H-pyrrole 1-oxide (7) ............ 35 
3.2.5 (2R,3R,4R)-3,4-Bis(benzyloxy)-2-((benzyloxy)methyl)pyrrolidine (9) .............................................. 36 
3.2.6 (1R,2R,3R)-2,3-Bis(benzyloxy)-1-((benzyloxy)methyl)-5-azaspiro[4.4]nonan-5-ium-bromide (10) . 37 
3.2.7 (1R,2R,3R)-2,3-Dihydroxy-1-(hydroxymethyl)-5-azaspiro[4.4]nonan-5-ium-bromide (11) .............. 38 
4  Appendix ..................................................................................................................................................... 42 
4.1 Spectra for compounds ................................................................................................................................ 42 
4.1.1 2,3,5-Tri-O-benzyl-L-xylofuranose (3) ................................................................................................ 42 
4.1.2 (2R,3R,4S, E) -2,3,5-Tris(benzyloxy)-4-hydroxypentanal O-(tert-butyldiphenylsilyl) oxime (5) ...... 44 
4.1.3 (2R,3R,4S, E)-2,3,5-Tris(benzyloxy)-4metylsulfonyloxypentanal O-(tert-butyldiphenylsilyl) oxime 
(6) .................................................................................................................................................................. 46 
4.1.4 (2R,3R,4R)-3,4-Bis(benzyloxy)-2-((benzyloxy)methyl)-3,4-dihydro-2H-pyrrole 1-oxide (7) ............ 48 
4.1.5 (2R,3R,4R)-3,4-Bis(benzyloxy)-2-((benzyloxy)methyl)pyrrolidine (9) .............................................. 50 
4.1.6 (1R,2R,3R) -2,3-Bis(benzyloxy)-1-((benzyloxy)methyl) -5-azaspiro[4.4]nonan-5-ium-bromide (10)
 ....................................................................................................................................................................... 52 
4.1.7 (1R,2R,3R)-2,3-Dihydroxy-1-(hydroxymethyl)-5-azaspiro[4.4]nonan-5-ium-bromide (11) .............. 54 
 
 
     
1  Introduction   
 
1.1 Alzheimer’s disease 
Alzheimer’s disease (AD) is a neurological disorder named after the German psychiatrists Alois 
Alzheimer. Amyloid–beta peptide (Ab) accumulation in the most affected areas of the brain 
results in formation of neurotic plaques and neurofibrillary tangles. Alois Alzheimer was the 
first one to notice the presence of amyloid plaques and an extreme loss of neurons while 
inspecting the brain of patients with AD.[1] The most common symptom of AD is dementia 
which is characterized by the loss of memory, cognitive functioning and behavioral abilities. In 
the early stages of the disease the symptoms are just beginning to affect a person’s functioning 
in common daily activities. As the disease progresses to a more severe stage, the person must 
depend completely on daily caregiving for basic activities of living.[2] Today, the disease is 
responsible for 60–70% of the senile dementia cases around the globe[3] and it is approximated 
that it can cause death 3–9 years after a person has been diagnosed with the disease.[4] 
 
At present, it is believed that at least 50 million people are living with AD worldwide and this 
number is projected to double every 20 years and will reach 152 million by 2050, if no cure is 
found.[5] The burden of AD affects individuals, their families, and the economy, with estimated 
global costs of US$ 1 trillion annually.[6] In Norway, the estimated amount of people with 
dementia is between 80 000–100 000 and the number is estimated to be around 160 000 within 
the next 30 years.[7] The annual societal costs related to AD in Norway are about 7,46 billion 
US$ and with the increasing number of Alzheimer's patients the cost will be as high as 14,5 
billion US$ in 2040.[8] Needles to mention, as the number of patients suffering from AD is 
steadily increasing, there is going to be a challenge for the society to provide healthcare for all 
patients. For obvious reasons, there is an urgent need to develop drugs that can reverse or at 




     
1.2 AD’s Neuropathology     
The first known description of Alzheimer’s dates back to 1907.[10] Now, more than 100 years 
later and despite enormous effort and investments, there is still no cure developed for this fatal 
disease. The exact causative effects of Alzheimer’s are not fully understood,[11] however, 
factors that seem to play an essential role in the development of the disease are neuron loss, 
extracellular β-amyloid deposits, τ-protein hyperphosphorylation, and neurotransmitter system 
dysfunction.[12] Other factors, including age (which is the strongest trigger for developing the 
disease),[13] education, genetic aspect and dental health are among the expected factors to be 
involved in the progression of Alzheimer’s.[14] In addition, studies indicate that maintaining 
strong social connections and mental activity (neurological stimulation) lower the risk of 
cognitive decline and further Alzheimer’s. This may be due to the direct mechanism through 
which social and mental stimulation strengthen connections between nerve cells in the brain.[15] 
While age increases the risk of developing the disease, it is not a direct cause of Alzheimer’s. 
Most individuals with the disease are 65 or older, after which, the risk of Alzheimer’s doubles 
every five years. After the age of 85, the risk reaches nearly one-third. Another strong risk 
factor for AD is genetics. Those who have family members that have been affected by 
Alzheimer’s are more likely to develop the disease.[16] Because of the multifactorial ethology 
of the disease and that the exact causative effects have not been sorted, no cure for Alzheimer’s 










     
1.3 Cholinergic and Amyloid Hypothesis 
AD has for most of its time and to this day been considered a multifactorial disease, associated 
with several risk factors as mentioned previously. The underlying cause of the pathological 
changes in AD is still not discovered, but several hypotheses have been proposed for its cause. 
It is believed that an impairment in the cholinergic function and an alteration in amyloid β-
protein production initiate the disease. These two suggestions have led to the two main 
hypothesis for AD; the cholinergic hypothesis and the amyloid hypothesis.[1]  
 
1.3.1 Cholinesterases and Cholinergic Hypothesis 
Acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) are enzymes which belong to 
the group of cholinesterases. AChE catalyzes the hydrolysis of the neurotransmitter 
acetylcholine (ACh) into acetic acid and choline (Scheme 1) and is one of the most crucial 
enzymes for nerve response.[17] AChE is mainly associated with nerves and muscles, typically 
being found on the synapsies, while BuChE, also known as plasma cholinesterase, hydrolyses 
butyrylcholinesterase and is synthesized by the liver. 
Scheme 1. Acetylcholinesterase hydrolyzes acetylcholine into acetic acid and choline. 
In the 1970s, it was believed that cholinergic deficits were related to the enzyme, choline 
acetyltransferase (ChAT)[1], which is responsible for the synthesis of ACh. The cholinergic 
hypothesis of AD was proposed due to the critical role of ACh in cognitive functioning. The 
ACh-synthesis takes place in the cytoplasm of cholinergic neurons. ACh is synthesized from 
choline and acetyl-coenzyme A by the ChAT enzyme and transported to the synaptic vesicles 
by vesicular acetylcholine transporter (VAChT).  
 
 
     
In the brain, ACh has a crucial role in several physiological processes such as memory, 
attention, learning and other critical cognitive functions. According to the cholinergic 
hypothesis, AD is due to the reduction in ACh biosynthesis. Increasing the cholinergic levels 
by inhibiting AChE is considered to be one of the therapeutic strategies that can promote 
cognitive and neural cell function. Acetylcholinesterase inhibitors (AChEIs) are used to inhibit 
ACh degradation in the synapses, which results in continuous accumulation of ACh and 
activation of cholinergic receptors.[1]   
Inhibition of acetylcholinesterase is the most common approach to enhance the well-being of 
patients with mild to moderate AD. These drugs increase the duration of ACh in the cholinergic 
synapse, by inhibiting the AChE enzyme from breaking down the neurotransmitter 
acetylcholine. Such AD treatment is in line with the cholinergic hypothesis, which was 
presented over 40 years ago.[18] This premise has since then served as the basis for the majority 
of treatment strategies and drug development approaches for Alzheimer’s disease. Ab is 
believed to affect cholinergic neurotransmission and to cause a reduction in the choline uptake 
and release of ACh. It has been demonstrated that a loss on the cholinergic synapses and 
amyloid fibril formation are related to the neurotoxicity of Ab oligomers and with the 
interactions between AChE and Ab peptide.  
As a result, the cholinergic hypothesis is based on three concepts: (1)  reduced presynaptic 
cholinergic markers in the cerebral cortex, (2) severe neurodegeneration of nucleus basalis of 
Meynert (NMB) in the basal forebrain, which is the source of cortical cholinergic innervation, 
(3) and the role of cholinergic antagonists in memory decline compared to the agonists, which 
have the opposite effect.[1, 19] However, recent studies of the brain of patients who had mild 
cognitive impairment in the early stages of Alzheimer’s disease in which acetylcholinesterase 
activity was unaffected (or even up regulated) have, however, led some to challenge the validity 
of the hypothesis as well as the rationale for using cholinesterase inhibitors to treat the disorder, 




     
1.3.2 Amyloid Hypothesis  
For decades, it has been recognized that abnormal deposition of β-sheets in the central nervous 
system has had a strong interference with dementia, and this has led to the concept of the 
amyloid hypothesis.[21] The amyloid hypothesis offers a robust framework to explain the Aβ 
mediated pathogenesis in AD and has for a long time been associated with the disease. 
According to the hypothesis, accumulation of Aβ peptides in the hippocampus and entorhinal 
cortex is the driving force behind the AD pathogenesis.[21] The deposition of Aβ peptides can 
then lead to the decline in the cognitive abilities in AD patients.[21] It is believed that the 
accumulation of Aβ starts around 15–20 years before the appearance of any observable clinical 
symptoms.[21] Studies suggested that numerous types of Aβ aggregates, ranging from oligomers 
to fibrils, contributing to the progression of AD.[21]  
Nonetheless, the exact mechanisms of toxicity of Aβ oligomers are still under debate. Aβ 
oligomers bind to the plasma membranes of neurons and weaken the neuronal function by 
inducing synaptic dysfunction and mitochondrial dysregulation.[21] They can also activate 
glutamatergic synaptic transmission, oxidative stress, calcium dyshomeostasis, and 
inflammation which further contribute to the death and damage of brain cells.[21] All these 
reports suggest critical involvement of Aβ in AD progression and thus enormous effort has been 
directed towards stopping the formation of Aβ plaques. Either targeting Aβ alone or the 









     
1.4 The mechanism of AChE   
 
The principal role of AChE is the termination of transmission at the cholinergic synapses by 
rapid hydrolysis of the neurotransmitter ACh. Due to the crucial biological role of AChE, it has 
become the target of the first generation of anti-Alzheimer drugs.[22] 
 
X-ray analysis of the Torpedo californica acetylcholinesterase (TcAChE) revealed a catalytic 
triad nearby the bottom of a ~ 20 Å deep active gorge decorated with aromatic residues 
penetrating almost halfway into the enzyme.[23] The residues are highly conserved, and most of 
them can be assigned functional roles. Trp84 (Trp=tryptophane) and F330 (F=phenylaniline) 
are involved in the anionic- and esteratic subsite (AS and ES) of the catalytic site (CAS) 
establishing cation-π interactions with the quaternary ammonium group of the enzyme 
substrate. Therefore, these interactions stabilize the enzyme-substrate complex and are in 
general very important in biological systems. On the mouth of the gorge, there is a second 
binding site termed the peripheral anionic site (PAS). The PAS serves as a relay station for the 
substrate to the active site. Crystallographic studies have demonstrated the involvement of 
several of these conserved aromatic residues in interactions with acetylcholinesterase inhibitors 
via noncovalent interactions.[22] One such example is found in the complex between AChE and 
edrophonium (1) that is a very potent AChE inhibitor in which the quaternary ammonium group 
of the inhibitor establishes a cation-π interaction with a tryptophan residue in the CAS whereas 
the hydroxyl group in edrophonium participates in a hydrogen bond with the serin residue in 
the catalytic triad (Figure 1).   
 
The PAS plays a non-cholinergic function in the progress of AD as it has been found to promote 
the aggregation of Aβ protein into amyloid fibrils, which is involved in the formation of senile 
plaques.[24] In line with this observation, it has been found that AChEIs that bind exclusively to 
the PAS inhibit AChE promoted Aβ aggregation.[24] In addition, dual binding site AChEIs (i.e., 
inhibitors that bind simultaneously to the PAS and the CAS) have been found not only to inhibit 
the hydrolysis of ACh but also AChE promoted aggregation of Aβ protein,[24] which are both 
attractive targets for AD treatment.[24] Therefore the design of new types of inhibitors of AChE 
should be based on the hypothesis of the dual binding of AChE inhibitors.[17] 
 
     
 
Figure 1. The active site of AChE interacts with edrophonium (1) by cation-π interactions with a tryptophan 
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1.5 Traditional AChE Inhibitors 
The elucidation and characterization of the pathophysiology of AD suggests a plethora of 
targets for designing potential disease-modifying agents. These agents should, by definition, be 
able to alter the underlying pathophysiology of the disease and to demonstrate meaningful 
reduction in the rate of cognitive decline or in the progression of the disorder.[25] Three general 
disease-modifying approaches have been acknowledged for the treatment of AD; anti-amyloid, 
neuroprotective, and restorative. Thus far, three AChE inhibitors have been approved by the 
Food and Drug Administration (FDA) for the treatment of AD, which include donepezil (C), 
galantamine (E) and rivastigmine (D) (Figure 2).[3, 25] The most traditional inhibitors will be 
examined in greater detail in the following sections.   









     
1.5.1 Physostigmine  
Eserine, also known as physostigmine (A), that is a potent AChE inhibitor, was first isolated 
from Calabar beans in 1864. Physostigmine can cross the blood-brain barrier (BBB), but due 
to the short half-life time, this drug only has a narrow therapeutic index and presents various 
side effects. Its common side effects include diarrhea, stomach cramps, increased production 
of saliva and excessive sweating.[3] Due to these disadvantages, physostigmine failed in the 
clinical trials for the treatment of AD.   
 
1.5.2 Tacrine  
Tacrine (B), 9-amino-1,2,3-tetrahydroacridine, was first synthesized in the 1930s, and is a 
mixed AChE and BuChE inhibitor. Tacrine was originally used as a muscle relaxant antagonists 
and respiratory stimulant[3] before Heilbronn described the effect tacrine exhibits on AChE and 
BuChE in 1961. She demonstrated that the compound acts as a reversible inhibitor being partly 
competitive with the substrate ACh and a more than 1000 times more potent inhibitor of BuChE 
than of AChE.[17] Other than being and enzyme inhibitor, tacrine (B) was found to have other 
mechanisms which could explain the cholinergic effect. In electrophysiological studies with 
neurons of Lymnaea stagnali, tacrine inhibits a slow outward K+ current and consequently 
increases the duration of the action potentials. An action potential is a frequent sequence of 
changes in the voltage across a membrane which is determined at any time by the relative ratio 
of ions and the permeability of each ion.[26] Tacrine has been used for the treatment of patient 
with AD since the 1980s, and was approved by the Food and drug Administration (FDA) in 
1993 and then discontinued in 2013. The usage of tacrine is limited due to its many side effects, 
including nausea, vomiting, loss of appetite, diarrhea and clumsiness affecting a significant 
number of the patients.[3] Additionally, multiple-dosage regimens are required to maintain 
prolonged therapeutic activity, due to the short half-life of tacrine.[3] Tacrine interacts with the 
amino acid residues F330 and Trp84, which are present in the AS and ES of AChE and its 
molecular structure, B, is presented in Figure 2.[3]  
 
 
     
1.5.2b Synthesis of Tacrine 
The Friedländer reaction is an important approach to the synthesis of Tacrine (Scheme 2).[27] 
The Friedländer reaction is a well–known method for preparing quinolines and related bicyclic 
aza-aromatic compounds.[27] In its original form, the Friedländer reaction is the reaction 
between an ortho-aminobenzaldehyde and an aldehyde or ketone bearing α–methylene 
functionality. In this regard, condensation reactions between 2-aminobenzonitrile and 
cyclohexanone, have been recognized as an important and general approach to the synthesis of 
tacrine and its analogues. This reaction is performed in the presence of a Lewis acid, such as 
AlCl3, ZnCl2 or CuCl2, under solvent free conditions.[27] 
 
Scheme 2. Synthesis of tacrine from 2-aminobenzonitrile and cyclohexanone in the presence of a Lewis acid. 
 
1.5.3 Donepezil  
In 1996, the drug donepezil (C), sold under the trade name Aricept (Figure 2), was approved 
by the FDA for the treatment of mild to moderate AD. However, donepezil has presented 
various side effects, including insomnia, nausea, loss of appetite, diarrhea, muscle cramps and 
muscle weakness.[28] In addition to inhibit AChE, donepezil may have additional mechanisms 
of action that exceeds the neurotransmitter level. For instance it also acts at the molecular and 
cellular level in almost all stages involved in the pathogenesis of AD.[3] Donepezil (C) exhibits 
a unique molecular structure (illustrated in Figure 2) that causes simultaneous interactions with 
CAS and PAS in the active gorge of AChE.[3]  
 
 
     
1.5.4 Rivastigmine 
Rivastigmine (D), sold under the trade name Exelon (Figure 2), was approved for the treatment 
of mild to moderate AD in 2000.[3] Although the exact mechanism of action of rivastigmine is 
uncertain, it has been hypothesized that it may exert pharmacological action by increasing the 
cholinergic functions.[3] Rivastigmine is a dual AChE-BuChE inhibitor and it is a carbamate 
that binds to AChE, which cleaves rivastigmine into various phenolic derivatives that are 
rapidly excreted from the body.[3] The carbamate moiety binds to the ES of AChE with more 
affinity than that of the acetate moiety of ACh during ACh hydrolysis. Therefore, the enzyme 
is inactivated for a certain amount of time[3], offering an explanation to its unusually slow 
activation kinetics.[3] Rivastigmine has major side effects, including stomach pain, weight loss, 
diarrhea, loss of appetite, nausea and vomiting.[3]  
 
1.5.5 Galantamine 
Galantamine (E), marketed with the name Nivalin, is an alkaloid isolated from the Galanthus 
woronowij plant that has been used as a medicine in Eastern European countries for decades 
for the treatment of myopathy, myasthenia, and sensory and motor deficits associated with the 
CNS.[3] Galantamine has also been shown to bind to nicotinic cholinergic receptors and its 
activity against ChE was first identified in the 1950s.[3] Galantamine was approved for the 
treatment of AD in 2001.[3] Galantamine has since then shown to be effective in treating the 
cognitive symptoms of AD.[3] The main side effects of galantamine include severe nausea, 
stomach cramps, vomiting, irregular breathing, confusion, muscle weakness and watering 
eyes.[3] The chemical structure of galantamine (E) is presented in Figure 2. 
 
1.5.6 Metrifonate  
Metrifonate (F) (Figure 2) is a organophosphate AChE inhibitor.[3] Metrifonate can improve 
cholinergic neurotransmission via a pharmacologically active metabolite, 2,2-dichlorovinyl 
dimethyl phosphate, and has been tested for the treatment of AD.[3] Metrifonate administered 
once per day can improve the cognitive function of patients with mild to moderate AD.[3] The 
tolerability of metrifonate is good, but its long-term use causes adverse side effects, including 
problems with neuromuscular transmission and respiratory paralysis.[3] Therefore, the 
development of this drug was interrupted during Phase III of clinical trials.[3] 
 
     
1.6 The future of AChE inhibitor  
Since the discovery of the first AChE inhibitor, physostigmine, a large number of studies have 
been performed to identify more effective inhibitors. Traditional inhibitors are naturally derived 
agents, other inhibitors may include analogues of the traditional inhibitors, derivatives of 
natural compounds and hybrids of synthetic inhibitors. The future AChE  inhibitors may cause 
milder side effects than traditional ones and may have better BBB permeability and increased 
effectiveness.[3] In addition, these compounds are able to limit the progression of AD. Huge 
efforts have been made in the investigation of AChE inhibition,[3] but only a few  drugs have 
been tested in humans, such as the above-mentioned tacrine (B), donepezil (C) rivastigmine 
(D) and galantamine (E). Most of these inhibitors have only been scarcely studied in animal 
models or using in vitro and in silico models. For that reason, further studies in humans are 
required in order to investigate the safety, efficacy and toxicity of these drugs.[3] 
AChE inhibitors are not able to completely stop the progression of AD, and various single-
target drugs that have reached clinical trials were not able to effectively alter the state of patients 
with AD. Therefore, there is a need to develop multi-functional drugs that can target several of 
the pathological mechanisms involved in the progression of AD, including the decreased levels 
of ACh, protein misfolding and associated Aβ aggregation, hyperphosphorylation of τ protein, 
metal dyshomeostasis and oxidative stress. However, there has only been done a limited number 
of studies that have focused on the development of new multi-target drugs. According to the 
structure-activity relationship studies, the design of future novel potent multi-target inhibitors 
should contain the following characteristics;[3] 1) the presence of a positively charged nitrogen 
atom 2) the size of an alkyl chain that is attached to the nitrogen atom should be relatively small, 
such as a methyl group; 3) the presence of an oxygen atom that is able to form hydrogen bonds, 
such as an ester; 4) the presence of electron‐donating groups such as hydroxyl groups; and 5) 
the presence of a two‐carbon unit between the nitrogen and oxygen atoms. Especially, the size 




     
1.8 Iminosugars  
Iminosugars (G-J in Figure 3) are nitrogen-in-ring monosaccharide analogues in which the 
ring-oxygen atom is replaced by a nitrogen atom. Azasugars (K in Figure 3) are a similar type 
of monosaccharide mimetics that contain a nitrogen atom in place of a carbon atom.[29] The 
most important role of azasugars and iminosugars is their inhibitory potency of glycosidase, 
which is a result of their ability to be protonated at physiological pH (pH 7,4) and thereby 
resemble charged analogues of the transition state for enzymatic cleavage of glycosides. 
Because of their unique ability to inhibit the activity of glycosidases, aza- and iminosugars have 
been evaluated for the treatment of disorders such as diabetes, cancer, viral infections, and 
lysosomal storage disorders.[24] 
 
Figure 3. Structure of iminosugars (G-J) and azasugar (K). 
 
The biological activity of iminosugars goes beyond the inhibition of glycosidases. For instance, 
it has been found that some iminosugars behave as potent inhibitors of acetylcholinesterase, 
thereby increasing both the level and duration of acetylcholine in the central nervous system. It 
has been proposed that iminosugars in their protonated form, at least to some extent, resemble 
the charged substrate of ACh, which is an important aspect for generating interactions with the 







     
Objectives  
The goal of this BSc project was to install a permanent positive charge on the nitrogen atom of 
an iminosugar to obtain compound 11, which represents an acetylcholinesterase inhibitor 
candidate. We argued that the positive charge in compound 11 has the potential to establish 
cation-π interaction with the aromatic residues in the active gorge of AChE (Figure 4) in a 
similar way as edrophonium (1) (Figure 1). In addition, the hydroxyl groups in compound 11 
have the potential to establish hydrogen bonds with the residues in the active gorge of AChE 
and thus further strengthen the binding to AChE. 
 
Figure 4. The active site of AChE interacts with Target molecule (11) by cation-π interactions with a tryptophan 
residue in the CAS whereas the hydroxyl group participates in a hydrogen bond with the serine residue of the 































     
2  Results and discussion  
 
2.1.1 Protection of L-xylose to give the tetra-protected sugar 3 
In this thesis, the starting material of the synthetic pathway was L-xylose. In order to avoid 
unwanted reactions occurring on the highly reactive hydroxyl groups of the sugar, the starting 
material was subjected to a three-step procedure to protect its hydroxyl groups in the 2, 3, and 
5 positions. Firstly, the most reactive hydroxyl group, namely the one at the anomeric carbon 
was methyl-protected using the traditional Fischer glycosylation conditions; consisting of an 
acid catalyzed reaction between L-xylose and methanol to give the corresponding methyl-
glycoside (Scheme 3).[30] The mechanism is initiated by protonation of the hydroxyl group, 
followed by the elimination of a water molecule, leading to the formation of a resonance 
stabilized carbocation intermediate II (Scheme 3). The lone pair electrons of the alcohol then 
attack the newly formed carbocation, forming an oxonium ion III, from which a proton is then 
eliminated by electron rearrangement to give the desired methyl-glycoside 1 (Scheme 3). 
 
Scheme 3. Mechanism of Fischer–Helferich glycosylation of L-xylose to give the protected sugar 1. 
 
In the subsequent step, methyl glycoside 1 underwent global O-benzylation upon treatment with 
benzyl bromide in the presence of NaH in DMF to provide compound 2 (Scheme 4). Benzyl 
protection is preferably used over other protecting groups such as acetyl i.e., due to their ease 
to install, in addition they can be easily removed under mild reaction conditions.[31] Finally, the 
anomeric hydroxyl group of compound 2 was liberated upon treatment with HCl(aq) at elevated 
temperature to provide furanose 3 in 46% yield over three steps with only one purification 
(Scheme 4). 
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Figure 5. IR spectra showing that compound 3 exists in equilibrium with its cyclic and acyclic form.  
 
Upon obtaining the IR spectra of compound 3, evidence of the equilibrium between the cyclic 
3 and acyclic form 3a could be observed (Figure 5). The presence of a low-intensity C=O peak 
at 1734 cm-1 indicates the presence of the aldehyde functionality (highlighted in red color in 
Figure 5) in acyclic compound 3a (Figure 5). 
 
2.1.2 Condensation-silyl protection reaction sequence   
This reaction was performed with the motivation to incorporate a nitrogen nucleus into the 
sugar moiety for the target molecule and to silyl-protect the formed hydroxylamine. Silyl-
protection was performed to allow functionalization of the hydroxyl group in the 4-position 
(Scheme 5).  
 
 
Scheme 5. The equilibrium mixture of compound 3 undergoing incorporation of a nitrogen nucleus and silyl-
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Thus, when the equilibrium mixture of 3 and 3a is treated with hydroxylamine (generated in 
situ from hydroxylammonium chloride and sodium methoxide), it is likely that the equilibrium 
is forced towards aldehyde 3a according to the Le Châtelier’s principle when it reacts with the 
NH2OH-nucleophile to generate aldoxime 4 (Scheme 6).  
 
 
Scheme 6. Mechanism of the incorporation of nitrogen into the sugar moiety  
 
The formation of aldoxime 4 is initiated by a nucleophilic attack of NH2OH on the carbonyl 
carbon of 3a generating a tetrahedral intermediate from which water is eliminated to give 
aldoxime 4 (Scheme 6).  
Scheme 7. Mechanism of the silyl-protection of compound 5. 
 
In the following step, oxime 4 underwent selective O-silylation on the oxime functionality with 
tert-butyldiphenylsilyl chloride (TBDPSCl) promoted by imidazole to afford silylether 5 in 
48% yield over two steps from 3 (Scheme 7.). Imidazole acts as a base for the deprotonation of 
4 leaving the oxygen with lone pair electrons, initiating a nucleophilic attack onto the silyl 

































































     
2.1.3 Mesylation protection of compound 5 to yield compound 6  
Hydroxyl groups act as bad leaving groups because of their strong basic characteristics and 
must therefore be converted into better leaving groups. A classical way to convert a hydroxyl 
group to a good leaving group is to convert it into mesylates.[32] Following this line, alcohol 5 
was converted into mesylate 6 in 73-86% yield upon treatment with mesyl chloride in the 
presence of Et3N. This reaction was performed with the sole purpose to facilitate a good leaving 





Scheme 8. O-mesylation of hydroxide to yield the mesyl-protected 6.  
 
The base deprotonates the hydrogen on the mesyl chloride allowing for electron donation and 
integration of a negative charge on the carbon atom (Scheme 9). The lone pair electrons on the 
carbon then attack the sulfur atom which further breaks the sulfur-oxygen bond, generating a 
negative charge on the oxygen. The electron on the oxygen then forms a new double bond 
between sulfur and further expels Cl. Finally, the lone pair electrons on the hydroxide of 
compound 5 attack the sulfur and by electron transfer providing compound 6 in 87% yield 
(Scheme 9).  







































































     
2.1.4 Cyclisation to form zwitterion 7 
In this step of the synthesis, the silyl-protecting group was removed with the purpose to 
trigger the cyclisation of compound 6 into compound 7 (Scheme 10).  
 
Scheme 10. Cyclisation of 6 to form zwitterion 7. 
 
To produce the cyclic structure 7 the silyl protecting group in the acyclic compound 6 was 
removed by TBAF in refluxing toluene (Scheme 10). Presumably, this led to the formation of 
a reactive intermediate 6a (Scheme 11), in which the nucleophilicity of the nitrogen atom is 
sufficient to facilitate the intramolecular stereospecific SN2 substitution in the 4-position to 
form compound 7. An SN2 reaction is characterized by the synchronous formation of a new 
bond and the cleavage of an old one to give a 5-coordinate carbon transition state which rapidly 
falls apart to give the reaction product. In chiral molecules, an inversion of stereochemistry is 
further observed.  
 
Scheme 11. Mechanism of the deprotection to form zwitterion 7.  
This reaction was performed two times due to the poor results of 17% yield the first time. The 
reason being for the poor results the first time was proposed to be due to the usage of wet 
toluene. The water in toluene affects TBAFs ability to desilyate, possibly by creating a cage 
around the fluoride ion and disabling its effect. It has been shown from literature, that the 
desilylation efficiency of TBAF is greatly dependent by the water content of the TBAF reagent, 
and it should be 5% or less.[33] The second time this reaction was performed, anhydrous toluene 


































     
2.1.5 Reduction and deoxygenation reaction 
The main goal behind of this reaction sequence was to reduce the imine oxide moiety of 






Scheme 12. Reduction and deoxygenation reaction to furnish compound 9.  
 
Imine oxide 7 underwent a NaBH4/Zn reduction sequence via hydroxylamine 8 to provide 
pyrrolidine 9 in 67% yield (Scheme 13). The mechanism for the reduction with Zn is currently 
not fully understood.  
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2.1.6 Formation of the target N-spiro fused compound 10 via double substitution 
reaction 
This reaction was performed with the motivation to create the target N-spiro fused compound 
10 via a double substitution reaction with 1,4-dibromobutane under basic conditions (Scheme 
14). This reaction was performed two times with two different kinds of bases. The first time 
this reaction was performed Et3N was chosen as the base for the deprotonation of the amine. 
The target molecule was synthesized, but the NMR-spectra showed impurity of the Et3N salt 
(Figure 8) that could not be separated from 10 by silica column chromatography, which resulted 
in an incorrect mass balance and a yield exceeding 100%. The second time this reaction was 
performed NaOAc was used as a base for the deprotonation of the amine, which yielded the 
compound 10 in 77% with few impurities.  
 
Scheme 14. N-Spiro cyclization of pyrrolidine 9 with 1,4-dibromobutane to yield 10. 
 
 
Scheme 15. Proposed mechanism for the formation of compound 10.  
 
The formation of N-spiro fused compound 10 occurs via a double substitution reaction (Scheme 
15). The first step in the reaction is a nucleophilic attack by the lone pair electrons on the amine 
to the most electrophilic carbon on the alkyl halide. Then a base deprotonates the amine making 
the lone pair electrons on the amine available to initiate a second nucleophilic attack onto the 





























     
 
Figure 8. 1H-NMR-spectra of compound 10 showing both the pure compound and the compound with impurities.   
The red spectrum on the top shows compound 10 with the impurities highlighted by the green columns and the 










     
2.1.7 Benzyl deprotection to furnish target molecule 11 
The sole purpose of this reaction was to remove the benzyl protecting groups and to furnish the 
target molecule 11 (Scheme 16). The target molecule was obtained in quantitative yield. The 
Pd/C-catalyzed hydrogenation is often used for the removal of O-benzyl protective groups as a 
green sustainable method due to the easy removal and reuse of the catalyst. However, due to 
the strong coordination ability of amines to Pd, the catalytic activity gradually decreases 
depending on the extended contact time of the amines and Pd. Therefore, the usage of high 
pressure, high temperatures or acid catalysts can enhance the reaction rate and complete the 
deprotection. Addition of acetic acid and hydrochloric acid is believed to delay the poisoning 
rate of Pd/C.[34]  
 
 
Scheme 16. Benzyl deprotection to furnish target molecule 11.  
 
The palladium-on-carbon (Pd/C)-catalyzed hydrogenative deprotection of the O-benzyl groups 
was facilitated using a EtOH-AcOH solvent system (Scheme 16). This reaction was done both 
with and without acetic acid. The results showed that the presence of acetic acid was 





















     
2.2 Concluding remarks  
The N-spiro fused quaternary ammonium salt 11 was successfully synthesized in 7 steps with 
L-xylose as the starting material. Thus, the synthesis was commenced from L-xylose, which 
underwent a Fischer glycosylation benzylation-hydrolysis sequence to provide tri-O-benzylated 
furanose 3 in 46% yield over three steps. With furanose 3 in hand, a nitrogen nucleus in the 
form of an oxime group was incorporated in the anomeric position of 3 to provide an aldoxime 
4, which underwent regioselevtive O-silylation to afford the silylether 5 in 48% yield. In order 
to facilitate a good leaving group for the ring closure of compound 5, the hydroxyl group in the 
4-position underwent O-mesylation to afford mesylate 6 in 86% yield, which in turn underwent 
cyclization into zwitterion 7 when the silyl protecting group was removed in refluxing toluene 
in the presence of TBAF. The usage of anhydrous toluene yielded good results (74%) in 
comparison to wet toluene (17%) which yielded poor results due to the presence of water in 
contact with the TBAF reagent. Reduction and deoxygenation were performed on the zwitterion 
7 to furnish pyrrolidine 9 (67%). The N-spiro fused compound 10 was obtained by using 1,4 – 
dibromobutane and Et3N (104%). The 1H- NMR-spectra of 10 showed the impurities of the salt 
of Et3N which further led to the usage of a non-organic base NaOAc instead of Et3N yielding 
the compound 10 with no impurities (77%). In the final step, the benzyl groups were removed 
by employing palladium-catalyzed hydrogenation to afford the target compound 11 in 
quantitative yield.  
 
2.3 Future work 
We believe that our developed strategy to obtain compound 11 is applicable to synthesize an 
expanded library of spirocyclic ammonium compounds, which are also of pharmaceutical 
interest as potential acetylcholinesterase inhibitors. Compound 11 will undergo biological 
testing as a potential acetylcholinesterase inhibitor by Associate Professor Óscar Lopéz at the 






     
3  Experimental  
 
3.1  General  
 
3.1.1 Solvents and reagents  
All chemicals that were used for the procedures were obtained from Merck, VWR or Sigma 
Aldrich and used as supplied unless otherwise stated in the experimental procedures. 
 
3.1.2 Spectroscopic and spectrometric analysis 
Nuclear magnetic resonance (NMR) spectra were recorded on the Bruker Ascend TM  400 series, 
operating at 400 MHz for 1H and MHz for 13C, respectively. The chemical shifts (δ) are 
expressed in ppm relative to residual chloroform-d (1H, 7.26 ppm; 13C, 77.16 ppm), D2O (1H, 
4.79 ppm) and CD3OD (1H, 3.31 ppm; 13C, 49.00 ppm). Coupling constants (J) are given in 
Hertz (Hz) and the multiplicity is reported as: singlet (s), doublet (d), triplet (t), doublet of 
doublets (dd), multiplet (m) and broad singlet (brs). The assignments of signals in various NMR 
spectra were often assisted by conducting heteronuclear single-quantum correlation 
spectroscopy (HSQC) and/or heteronuclear multiple bond correlation spectroscopy (HMBC). 
Infrared (IR) spectra were recorded on the Agilent Cary 630 FTIR spectrometer. The samples 
were analyzed by direct placement onto the crystals of an attenuated total reflectance (ATR) 
module.[35] 
 
3.1.3 Chromatography  
Thin-layer chromatography (TLC) was carried out using aluminum backed 0.2 mm silica gel 
plates. The spots of the product were detected using ultraviolet (UV) extinction at λ=254 nm or 
λ=366 nm.  Flash column chromatography (FCC) was also carried out with silica gel, with 
solvent gradients that are indicated in the procedure. Flash chromatography (FC) was carried 




     
3.2 Methods  





AcCl (0.47 mL, 6.66 mmol, 0.2 equiv) was added dropwise to MeOH (70mL) before addition 
of L-xylose (5.0 g, 33.3 mmol, 1.0 equiv). The obtained mixture was kept stirring at RT for 5.5 
h. The temperature was then adjusted to 0°C before dropwise addition of aq NaOH (1M) until 
basic pH (8-9) was reached. The solvent was removed under reduced pressure and the resulting 
concentrate was co-evaporated three times from toluene. The residue was dissolved in anhyd 
DMF (106 mL) and NaH (60% dispersion in mineral oil, 7.3g, 176 mmol, 5.3 equiv) was added 
portionwise. The resulting suspension was kept stirring at RT under an argon atmosphere for 
10 min. The temperature was then decreased to 0°C and BnBr (20 mL, 167 mmol, 5.0 equiv) 
was added dropwise. The mixture was then kept stirring overnight at RT. The temperature was 
adjusted to 0°C before dropwise addition of H2O (167 ml). The aqueous mixture was extracted 
with EtOAc (2 x 167 mL) and the combined organic layers were dried (MgSO4), filtered, and 
concentrated under reduced pressure. The residue was dissolved in 1,4-dioxane (100 mL) and 
aq HCl (100 mL 4 M) and the mixture was kept stirring at 60-65°C for 2 days. The aqueous 
mixture was extracted with EtOAc (2 x 125 mL) and the combined organic layers were 
concentrated under reduced pressure. The residue was purified by silica gel flash column 
chromatography (PE-EtOAc, 4:1 → 7:3, v/v) to provide 6.41 g (46%) of a colorless syrup.[29] 
Rf = 0.35 (PE-EtOAc, 4:1, v/v) 
IR (ATR): νmax		3447, 3063, 3029, 2921, 2865, 1734, 1453, 1053, 733 cm-1. 
1H-NMR (CDCl3, 400 MHz) ẟ: 3.60-3.71 (m, 2.4H) 3.83-3.88 (m, 1.2H), 3.93-3.97 (m, 1.2H), 
4.02-4.04 (m, 0.8H), 3.31-4.33 (m, 1,2H), 4.41-5.57 (m, 5.6H), 5.16-5.19 (m, 0.8H), 5.40 (dd, 
0.4H, J = 4.0 Hz, J = 9.2 Hz), 7.17-7.31 (m, 15H). 
13C-NMR (CDCl3, 100 MHz) ẟ: 68.4, 68.8, 72.0, 72.2, 72.4, 72.8, 73,2, 73.6, 73.8, 77.5, 80.0, 






     






A solution of sodium methoxide methanol in situ (9 mL, 44.4 mmol, 4 equiv) was added to a 
solution of 3 (4.68 g, 11.1 mmol, 1.0 equiv) and hydroxylamine hydrochloride (6.19 g, 88.8 
mmol, 8.0 equiv) in MeOH (70 mL). The obtained mixture was kept stirring at RT for 2 h before 
the solvent was removed under reduced pressure. The residue was dissolved in 100 mL of water 
and 100 mL of EtOAc, then the phases were separated, and the organic extract was dried, 
filtered and concentrated. The crude product was further dissolved in toluene and concentrated 
under reduced pressure two times, before DCM (24 mL) and imidazole (0.98 g, 14.5 mmol, 1.3 
equiv) were added to the solution. After this, TBDPS-Cl (3.60 mL, 13.9 mmol, 1.25 equiv) was 
added portionwise and the resulting mixture was kept stirring at RT for 30 min. The mixture 
was then diluted by addition of water/DCM (50 mL, 1:1 v/v) and extracted with DCM (3 x 50 
mL). The combined organic phases were dried (MgSO4), filtered and concentrated under 
reduced pressure. Purification by flash column chromatography (PE-EtOAc, 9:1 → 17:3, v/v) 
yielded 4.06 g (54%) of a yellow oil.[36] 
Rf = 0.11 (PE-EtOAc, 9:1, v/v) 
IR (ATR): νmax		3500, 3030, 2930, 2857, 1736, 1453, 1239, 912, 694 cm-1. 
The 13C NMR and 1H NMR for compound 5 was never properly assigned as it decomposed in 
the NMR solvent (CDCl3), presumable due to the presence HCl residues. In addition, compound 








     
3.2.3 (2R,3R,4S,E)-2,3,5-Tris(benzyloxy)-4-metylsulfonyloxypentanal O-(tert-





MsCl (0.3 mL, 3.84 mmol, 1.17 equiv) and NEt3 (0.7 mL, 5.08 mmol, 1.5 equiv) were slowly 
added to a solution of 5 (2.21g, 3.28 mmol, 1.0 equiv) in DCM (10 mL) under an argon 
atmosphere at 0°C. The mixture was kept stirring for 30 minutes, before water (2.7 mL) was 
added. Then the mixture was diluted by addition of water/DCM (20 mL, 1:1 v/v) and extracted 
with DCM (3 x 20 mL). The organic layers were then dried (MgSO4) and concentrated under 
reduced pressure. Purification by flash column chromatography (PE-EtOAc, 7:1 → 33:7, v/v) 
yielded 2.13 g (86%) of a yellow oil.[37] 
Rf = 0.42 (PE-EtOAc, 7:1, v/v) 
IR (ATR): νmax		3030, 2931, 2858, 1735, 1357, 1175, 910, 695 cm-1. 
The 13C NMR and 1H NMR for compound 6 was never properly assigned as it decomposed in 
the NMR solvent (CDCl3), presumable due to the presence HCl residues. In addition, compound 






















TBAF (7,07 mL, 1M in THF, 7.068 mmol, 1.55 equiv) was slowly added to a solution of 6 
(3.43 g 4.56 mmol, 1.0 equiv) in toluene (56 mL). The reaction was then heated to reflux for 
45 minutes before being allowed to cool to RT. The residues were taken up in DCM (30 mL), 
water (60 mL) was added to the aqueous phase and extracted with DCM (3 x 30 mL), before 
the combined organic layers were concentrated under reduced pressure. Purification by flash 
column chromatography (PE-EtOAc-MeOH, 1:1:0 à 0:1:0 à 0:39:1, v/v) yielded 1.41 g (74 
%) of a white powder.[36] 
Rf = 0.59 (PE-EtOAc, 1:1, v/v) 
IR (ATR): νmax		3166, 3049, 2922, 2883, 1591, 1275, 1086, 696 cm-1.	
1H-NMR (CDCl3, 400 MHz) dH: 3.70 (dd, 1H, J = 2.3 Hz, J = 10.0 Hz), 3.93-3.99 (m, 2H), 
4.30 (dd, 1H, J = 2.2 Hz, J = 3.5 Hz), 4.23-4.50 (m, 5H), 4.54 (d, 1H, J = 12.0 Hz), 4.59-4.60 
(m, 1H), 6.82 (brs, 1H), 7.19-7.29 (m, 15H)  
13C-NMR (CDCl3, 100 MHz) dC: 66.3, 71.8, 72.1, 73.6, 77.6, 80.5, 83.0, 127.8, 127.9, 128.0, 









     





NaBH4 (0.26 g, 6.76 mmol) was added to a solution of 7 (1.41 g, 3.38 mmol, 1.0 equiv) in 68 
ml of EtOH. The mixture was stirred at RT for 16 h, until a TLC analysis (PE-EtOAc, 1:1, v/v) 
showed the disappearance of the starting material (Rf = 0.50) and the formation of a new product 
(Rf = 0.80). MeOH (5.6 mL) and water (16.9 mL) water were then added. The mixture was 
allowed to warm to RT and stirred for another 3 h, before it was evaporated under reduced 
pressure and the crude obtained was filtered through Celite by the aid of diethyl ether. The 
collected filtrate was evaporated under reduced pressure. The residue was dissolved in 45 mL 
of acetic acid, before Zn powder (3.57 g, 54.6 mmol, 20.0 equiv) and water (45 mL) were added. 
The reaction mixture was stirred at RT for 1.5 h until a TLC analysis (DCM-MeOH, 39:1, v/v) 
showed the disappearance of the starting material (Rf = 0.43) and the formation of a new product 
(Rf = 0.34). The mixture was filtrated through cotton, concentrated under reduced pressure and 
then saturated aqueous solution of Na2CO3 was added at 0°C until basic pH was realized. After 
extraction with EtOAc (3 x 30 mL), the organic layers were concentrated under reduced 
pressure and the crude was purified by flash column chromatography (DCM-EtOAc, 1:1 à 
13:7, v/v) to yield 910 mg (67 %) of colorless oil.[38] 
Rf = 0.082 (DCM-EtOAc, 1:1, v/v) 
IR (ATR): νmax  3062, 2857, 1453, 1363, 1071, 907, 731, 694 cm-1. 
1H-NMR (CDCl3, 400 MHz) dH: 2.15 (brs, 1H), 3.01 (d, 2H, J = 3.1 Hz), 3.15-3.17 (m, 1H), 
3.46-3.55 (m, 2H), 3.79-3.80 (m, 1H), 3.93 (brs, 1H), 4.36-4.49 (m, 6H), 7.16-7.27 (m, 15H)  
13C-NMR (CDCl3, 100 MHz) dC: 51.2, 64.3, 70.5, 71.2, 72.0, 73.3, 84.7, 85.9, 127.7-128.5 













Method 1. To a solution of 9 (69.5 mg, 0.17 mmol, 1.0 equiv) in THF (2.5 mL), NEt3 (118 µL, 
0.85 mmol, 5 equiv) and 1,4 – dibromobutane (124 µL, 1.037 mmol, 6.1 equiv) were added. 
The reaction mixture was stirred at RT for 6 days until a TLC analysis (DCM-MeOH, 4:1, v/v) 
showed the disappearance of the starting material (Rf = 0.89) and the formation of a new product 
(Rf = 0.80). MeOH was then added, and the solution was evaporated under reduced pressure. 
The crude was purified by flash column chromatography (DCM-MeOH, 19:1 à 9:1, v/v) to 
provide 145 mg (104 %) of a mixture containing 54% of 10 and 46% of the salt of triethylamine 
which was verified from 1H NMR spectroscopy.  
Method 2. To a solution of 9 (104 mg, 0.26 mmol, 1.0 equiv) in THF (5 mL), NaOAc (107 mg, 
1.3 mmol, 5 equiv) and 1,4 – dibromobutane (200 µL, 1.6 mmol, 6.1 equiv) were added. The 
reaction mixture was stirred at RT for 6 days until a TLC analysis (DCM-MeOH, 4:1, v/v) 
showed the disappearance of the starting material (Rf = 0.82) and the formation of a new product 
(Rf = 0.71). MeOH was then added, and the solution was evaporated under reduced pressure. 
The crude was purified by flash column chromatography (DCM-MeOH, 19:1 à 187:13, v/v) 
to yield 108 mg (77 %) of a white crystal. 
Rf = 0.23 (DCM-MeOH, 19:1, v/v) 
IR (ATR): νmax	 3030, 2939, 2869, 1454, 1096, 1023, 729 cm-1. 
1H-NMR (CD3OD, 400 MHz) dH: 2.15 (s, 4H), 3.65-3.70 (m, 3H), 3.79-3.99 (m, 5H), 4.05-
4.09 (m, 1H), 4.29 (dd, 1H, J=1.7, J=5.8), 4.37 (brs, 1H), 4.50-4.61 (m, 6H), 7.31-7.34 (m, 15H) 
13C-NMR (CD3OD, 100 MHz) dC: 22.1, 22.9, 60.3, 66.0, 66.9, 67.5, 73.1, 73.3, 74.4, 76.7, 











Compound 10 (16.4 mg, 0.0300 mmol, equiv 1) dissolved in EtOH (2 mL) was added 10 wt% 
of Pd/C (35 mg). The obtained mixture was kept stirring under a hydrogen atmosphere at 30 °C 
for 2 days. After this time acetic acid (2 mL) was added, and the reaction mixture was then 
stirred under a hydrogen atmosphere at 30 °C for another 4 days. The reaction mixture was then 
filtered through Celite and EtOH was evaporated. The total yield of this reaction was 14.7 mg 
in quantitative yield.  
IR (ATR): νmax	 3276, 2924, 2853, 1570, 1412, 1082, 925, 731 cm-1. 
1H-NMR (D2O, 400 MHz) dH: 2.14-2.27 (m, 4H), 3.60-3.90 (m, 7H), 4.13 (d, 2H, J=4.7 Hz), 
4.31 (dd, 1H, J=3.7 Hz, J=6.9 Hz), 4.48-4.49 (m, 1H) 
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4  Appendix 
 
4.1 Spectra for compounds  
 



























     















     
4.1.3 (2R,3R,4S, E)-2,3,5-Tris(benzyloxy)-4metylsulfonyloxypentanal O-(tert-





























































     






























     













































     
 
